What Fulgent Genetics, Inc. does.

We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs.

Founded in 2011, Fulgent began with two simple ideas: flexibility and affordability. We offer and develop flexible and affordable diagnostic and genetic tests and laboratory services designed to improve patient care and quality of life. We strive to provide the most effective and wide-ranging genetic and diagnostic testing menu on the market. Our long-term vision is to transform from a diagnostic business into a fully integrated precision medicine company.

We have broad testing capabilities with a testing services menu that is scalable and affordable for our customers. Our testing services include:

Revenue and profit, by fiscal year.

More on FLGT.

• Fulgent Genetics, Inc. summary
• Fulgent Genetics, Inc. financial statements
• Fulgent Genetics, Inc. key metrics
• Fulgent Genetics, Inc. health scores and style box
• Fulgent Genetics, Inc. earnings
• Fulgent Genetics, Inc. dividends
• Fulgent Genetics, Inc. valuation
• Fulgent Genetics, Inc. ownership and insiders
• Fulgent Genetics, Inc. peers

Figures from Fulgent Genetics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.